SUSPECT PULMONARY FIBROSIS

—a common threat across a wide range of interstitial lung diseases (ILDs), including connective tissue disease-associated interstitial lung diseases (CTD-ILDs). Pulmonary fibrosis can become a key driver of irreversible harm and early mortality, and calls for urgent identification and intervention.1-4

Find out more about the critical threat
Patient showing a lung scan
Patient showing a lung scan
Patient showing a lung scan
Patient showing a lung scan

How to break bad news to your patients

Breaking bad news in pulmonary fibrosis can be difficult for both patients and physicians.
Professor Walter Baile, psychiatrist and co-founder of the SPIKES model leads us
through a communications approach to help improve conversations.

Watch the film series

HRCT QUIZ

What can you uncover from an ILD patient's HRCT scan?

Time to complete: approx. 3 mins

IMAGING ATLAS OF INTERSTITIAL LUNG DISEASES

This atlas assists you through the process of diagnosing an ILD, helping you recognise key clues and characteristics.

DOWNLOAD
THE IMAGING ATLAS

THE CRITICAL THREAT OF PULMONARY FIBROSIS

See what Vincent Cottin, Professor of Respiratory Medicine, has to say about the threat of pulmonary fibrosis across a range of ILDs

PREVALENCE & PROGRESSION OF PULMONARY FIBROSIS

See what Clive Kelly, Senior Lecturer, has to say about the prevalence of pulmonary fibrosis in patients with connective tissue diseases

YOUR VIGILANCE CAN MAKE A DIFFERENCE

Pulmonary fibrosis is an insidious, unpredictable threat.

Understand the pathophysiology of pulmonary fibrosis and hear an
expert's view on the threat across a range of ILDs.

FIND OUT MORE ABOUT THE THREAT
References

  1. 1.

    Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of ... in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.

  2. 2.

    Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc. 2013;10(4):362-370.

  3. 3.

    Caban JJ, Yao J, Bagci U, Mollura DJ. Monitoring pulmonary fibrosis by fusing clinical, physiological, and computed tomography features. Conf Proc IEEE Eng Med Biol Soc. 2011;6216-6219.

  4. 4.

    Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, on behalf of the IPF Consensus Working Group. What’s in a name? That which we call IPF, by any other name would act the same. Eur Resp J. 2018;51:1800692.